(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/212384 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61K 31/5377* (2006.01)
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/022358

(22) International Filing Date:
29 March 2022 (29.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/167,599 29 March 2021 (29.03.2021) US
63/277,134 08 November 2021 (08.11.2021) US

(71) Applicant: **JUNO THERAPEUTICS, INC.** [US/US]; 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109 (US).


(72) Inventors: **TREDE, Nikolaus Sebastian**; 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109 (US). **PULHAM, Tim**; Route de Perreux 1, CH-2017 Boudry (CH). **WU, Fan**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **POURDEHNAD, Michael**; 1500 Owens Street, San Francisco, California 94158 (US). **DESTEFANO, Joseph Andrew**; 86 Morris Avenue, Summit, New Jersey 07901 (US). **CARRANCIO ANTON, Maria Soraya**; 10300 Campus Point Drive, San Diego, California 92121 (US). **BUCHHOLZ, Tonia Jane**; 1500 Owens Street, San Francisco, California 94158 (US). **PORTS, Michael**; 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109 (US). **QIN, Jim**; 400 Dexter Ave. N, Suite 1200, Seattle, Washington 98109 (US).

(74) Agent: **TRAN, Tam-Tammy** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,

(54) Title: COMBINATION OF A CAR T CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FOR TREATMENT OF LYMPHOMA

FIG. 1



(57) Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, *e.g.*, T cell therapy, and the use of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.

WO 2022/212384 A1

[Continued on next page]

RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*